Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nisin is a **polycyclic antibacterial peptide** produced naturally by the bacterium *Lactococcus lactis* and some other Gram-positive bacteria including certain *Streptococcus* species[1][5]. It belongs to the **lantibiotic** class, specifically Type A (I) lantibiotic, and is a **bacteriocin** classified as a ribosomally synthesized and post-translationally modified peptide (lanthipeptide)[1][4][5]. Nisin demonstrates broad-spectrum antimicrobial activity, especially against Gram-positive bacteria and spores[1][3][5]. Its mechanism involves **disruption of bacterial cell membrane integrity by forming pores and dissipating membrane potential**[5]. Nisin is **FDA-approved as a safe food preservative (GRAS status)**, but research in recent years demonstrates its additional potential for biomedical use, including treatment of drug-resistant bacterial infections, anti-biofilm activity, immunomodulatory effects, and even selective antitumor (anticancer) properties[1][2][3][6]. Nisin is effective in synergy with other drugs as well as alone, and it is utilized predominantly via fermentation processes rather than chemical synthesis[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nisin.